CTOs on the Move

Calysta Energy

www.calystaenergy.com

 
Calysta, Inc. (www.calysta.com), Menlo Park, CA, is an innovator in industrial products for food and energy security. Calysta has two business units. Calysta Nutrition is developing and commercializing FeedKind™ protein, a natural, safe, non-GMO sustainable ingredient for fish feed and other applications. FeedKind™ protein is approved for sale in the European Union. Calysta Energy is developing high value industrial and chemical products with cost and performance advantages over current processes.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Calysta Energy raised $48M on 02/02/2016

Similar Companies

Enzo

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem`s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Harbor Therapeutics

Harbor Therapeutics is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Code Biotherapeutics

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to treat the untreatable and cure the incurable. Code Bio is developing highly targeted genetic medicines with its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with the delivery of genetic medicines. 3DNA offers unparalleled tissue and cell targeting specificity, improved bioavailability, capability to deliver large genetic payloads, potential ability to re-dose, and a scalable, modular, reproducible manufacturing process. Our 3DNA delivery platform is poised to transform the field of genetic medicines, enabling targeted delivery of gene therapy, RNAi and other genetic modalities. Currently we are advancing an internal pipeline of genetic medicines focused on select diseases without a cure (Duchenne`s Muscular Dystrophy and Type 1 Diabetes), as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Exagen Diagnostics

Exagen Diagnostics, Inc. is committed to providing excellent service to our physicians, patients and partners.

Vytelle

With Vytelle, cattle producers increase accuracy of feed intake and bodyweight measurement, improve certainty of genetic selection and accelerate progress.